

## Erratum

### Deep learning in fracture detection: a narrative review

Pishtiwan H S KALMET <sup>1\*</sup>, Sebastian SANDULEANU <sup>2\*</sup>, Sergey PRIMAKOV <sup>2</sup>, Guangyao WU <sup>2</sup>, Arthur JOCHEMS <sup>2</sup>, Turkey REFAEE <sup>2</sup>, Abdalla IBRAHIM <sup>2-5</sup>, Luca v. HULST <sup>1</sup>, Philippe LAMBIN <sup>2,3</sup>, and Martijn POEZE <sup>1,6</sup>

Acta Orthopaedica 2020; 91 (2): 215–220. DOI 10.1080/17453674.2019.1711323

#### Correction of affiliations:

\* Shared first authorship

<sup>1</sup> Maastricht University Medical Center+, Department of Trauma Surgery, Maastricht; <sup>2</sup> The D-Lab: Decision Support for Precision Medicine, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht; <sup>3</sup> Department of Radiology and Nuclear Medicine, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands; <sup>4</sup> Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, Hospital Center Universitaire De Liege, Liege, Belgium; <sup>5</sup> Department of Nuclear Medicine and Comprehensive diagnostic center Aachen (CDCA), University Hospital RWTH Aachen University, Aachen, Germany. <sup>6</sup> Nutrim School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands  
Correspondence: pishtiwan.kalmet@mumc.nl

#### Correction of conflict of interest statement

*Original statement:* The authors declare that they have no conflict of interest.

#### Corrected version:

#### Conflict of interest

The authors, except dr. Philippe Lambin, declare that they have no conflict of interest. Dr. Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures and DualTpharma. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV, Merck and Convert pharmaceuticals. Dr Lambin has shares in the company Oncoradiomics SA and Convert pharmaceuticals SA and is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures.